Modern dosing of bivalirudin was evaluated in the REPLACE-2 trial, which randomized 6010 patients undergoing elective or urgent PCI [7] to UFH with planned GPIIb/IIIa or bivalirudin with ...

A typical platelet count range can change with age. Platelet counts may fluctuate due to natural vascular aging, changes in bone marrow tissue, and altered blood plasma makeup. Platelets ...

The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet aggregation.

The acquisition of resistance to anoikis, the cell death induced by loss of adhesion to the extracellular matrix, is an absolute requirement for the survival of disseminating and circulating tumour ...

Binding of both von Willebrand factor and fibrinogen to the platelet receptor glycoprotein, GPIIb/IIIa, is reduced in uraemia, leading to impaired platelet adhesion to the subendothelium. The kidney ...

Until recently, research has focused on uncovering individual pathways to target. As more of the pathophysiology of sepsis has become understood and more biomarkers uncovered, the interplay between ...

While this may not eliminate DAPT, it may significantly decrease the duration of therapy. These two approaches conflict somewhat. Coatings that prevent the attachment of platelets may also delay ...

Advanced Science. 2023. Vol. 10:e2302123 Zhang W, Sun M, Liu Y, Zhang Y, Xu L, Luo Y, et al.. Platelet Membrane-Functionalized Hollow Mesoporous Prussian Blue Nanomedicine for Comprehensive ...

Examination showed a normal blood pressure, weight of 95 kg and no signs of heart failure or organomegaly. Haemoglobin was 13.9 g/dl, platelets 174 000, and coagulation profiles were normal. Cardiac ...